Evidence map›Paper›PMID 41270956›Full record

ArticleJournal of advanced research2026

Dysregulated ITGA3/FAK/YAP axis mediates impaired alveolar type II epithelial cells function in COPD.

Li Liu, Suye Zhong, Tengfei Zhou, Yixing Wu, Weiping Hu, Xiao Wang, Yue Ren, Kankai Wang, Xinhua Lin, Jing Zhang

Abstract read
In one paragraph

Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Li LiuDepartment of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Suye ZhongThe State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai 200438, China.
Tengfei ZhouDepartment of Physiology, Zhejiang University School of Medicine, Hangzhou 310058, China.
Yixing WuDepartment of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Weiping HuDepartment of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Xiao WangDepartment of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Yue RenDepartment of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
Kankai WangDepartment of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China. Electronic address: kankai.wang@zju.edu.cn.
Xinhua LinThe State Key Laboratory of Genetic Engineering, School of Life Sciences, Zhongshan Hospital, Fudan University, Shanghai 200438, China. Electronic address: xlin@fudan.edu.cn.
Jing ZhangDepartment of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Electronic address: zhang.jing@zs-hospital.sh.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAlveolar regeneration deficiency may lead to persistent emphysematous destruction in chronic obstructive pulmonary disease (COPD), lacking effective treatments to halt disease progression. Dysfunction of alveolar type II epithelial cells (AT2 cells), which serve as the progenitor in distal lung, is thought to be a major cause of alveolar regeneration deficiency. However, the mechanisms underlying AT2 cells dysfunction following injury and alveolar regeneration deficiency in COPD remain poorly understood.

objectivesWe aim to elucidate molecular mechanisms underlying impaired AT2 progenitor function, and better understand regeneration defects in COPD by integrating scRNA-seq analysis, chronic cigarette smoke-exposed murine model and alveolar organoid.

methodsChronic cigarette smoke (CS)-exposed murine model was established to evaluate emphysematous destruction and AT2 cells function through immunostaining and organoid assays. Integrated analysis of patient and CS-exposed mice derived single-cell RNA sequencing data was performed to identify transcriptional alterations in AT2 cells. Focusing on the identified ITGA3, we performed functional validation and mechanistic investigation via genetic manipulation and pharmacological interventions in organoid as well as in vivo pharmacological interventions upon CS injury.

resultsChronic CS exposure impaired AT2 cells proliferation and self-renewal capacity. Single-cell profiling revealed disrupted proliferation pathways and ITGA3 downregulation in AT2 cells. Mechanistically, ITGA3 regulates AT2 cells self-renewal function defects upon injury through FAK/YAP axis. And CS-induced reactive oxygen species (ROS) accumulation contributed to ITGA3 suppression and regenerative impairment. In vivo scavenging ROS with NAC restored CS-induced ITGA3 loss in AT2 cells, reactivated FAK/YAP signaling and ameliorated emphysematous pathology.

conclusionOur study elucidates core regulatory role of ROS/ITGA3/FAK/YAP axis in AT2 cells renewal dysfunction in COPD by integrating single-cell genomics, preclinical models, and functional organoid studies, demonstrating ROS/ITGA3 as a new promising avenue for therapeutic intervention of COPD regeneration therapy.

Indexed as

Alveolar Epithelial CellsFocal Adhesion Kinase 1Integrin alpha3Pulmonary Disease, Chronic ObstructiveAnimalsDisease Models, AnimalHumansMaleMiceMice, Inbred C57BLSignal TransductionYAP-Signaling ProteinsFocal Adhesion Kinase 1Integrin alpha3Ptk2 protein, mouseYap1 protein, mouseYAP-Signaling ProteinsAlveolar organoidAT2 progenitorCOPDITGA3Regeneration

Identifiers

PMID41270956
PMCPMC13453853

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.